Associations between seattle heart failure model scores and health utilities: Findings from HF-ACTION

Journal of Cardiac Failure

Volumn 19, Issue 5, 2013, Pages 311-316

  Li, Yanhong ^a   Neilson, Matthew P ^c   Whellan, David J ^d   Schulman, Kevin A ^a,b   Levy, Wayne C ^e   Reed, Shelby D ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost benefit analysis; disease management; heart failure; mortality; quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SEATTLE HEART FAILURE MODEL SCORE;

AGED; FEMALE; HEALTH STATUS; HEART FAILURE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 84879808316     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.03.008     Document Type: Article

References (21)

1. J. Gonseth, P. Guallar-Castillón, J.R. Banegas, and F. Rodríguez-Artalejo The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports Eur Heart J 25 2004 1570 1595
2. E. Lambrinou, F. Kalogirou, D. Lamnisos, and P. Sourtzi Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: a systematic review and meta-analysis Int J Nurs Stud 49 2012 610 624
3. D.A. Turner, S. Paul, M.A. Stone, A. Juarez-Garcia, I. Squire, and K. Khunti Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care Heart 94 2008 1601 1606
4. TEAM-HF: Tools for the Economic Analysis of Patient Management Interventions in Heart Failure. Available at: http://team-hf.org. Accessed February 12, 2013.
5. W.C. Levy, D. Mozaffarian, D.T. Linker, S.C. Sutradhar, S.D. Anker, and A.B. Cropp The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
6. Reed SD, Li Y, Ellis SJ, Whellan DJ, Schulman KA, O'Connor CM, et al. Seattle Heart Failure Model scores significantly predict medical resource use and costs in HF-ACTION. Presented at: 2011 Annual Scientific Meeting of the Heart Failure Society of America; Boston, Massachusetts, September 18-21, 2011.
7. D.J. Whellan, C.M. O'Connor, K.L. Lee, S.J. Keteyian, L.S. Cooper, and S.J. Ellis Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): design and rationale Am Heart J 153 2007 201 211
8. C.M. O'Connor, D.J. Whellan, K.L. Lee, S.J. Keteyian, L.S. Cooper, and S.J. Ellis Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439 1450
9. R. Rabin, and F. de Charro EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 2001 337 343
10. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press Oxford
11. S.D. Reed, K.J. Anstrom, J.A. Ludmer, G.A. Glendenning, and K.A. Schulman Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia Cancer 101 2004 2574 2583
12. A.S. Pickard, C.T. Wilke, H.W. Lin, and A. Lloyd Health utilities using the EQ-5D in studies of cancer Pharmacoeconomics 25 2007 365 384
13. J.W. Shaw, J.A. Johnson, and S.J. Coons US valuation of the EQ-5D health states: development and testing of the D1 valuation model Med Care 43 2005 203 220
14. G. Yao, N. Freemantle, M. Flather, P. Tharmanathan, A. Coats, and P.A. Poole-Wilson Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model Pharmacoeconomics 26 2008 879 889
15. G. Yao, N. Freemantle, M.J. Calvert, S. Bryan, J.C. Daubert, and J.G. Cleland The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator Eur Heart J 28 2007 42 51
16. A. Göhler, A. Conrads-Frank, S.S. Worrell, B.P. Geisler, E.F. Halpern, and R. Dietz Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure Eur J Heart Fail 10 2008 1026 1032
17. D.C. Chan, P.A. Heidenreich, M.C. Weinstein, and G.C. Fonarow Heart failure disease management programs: a cost-effectiveness analysis Am Heart J 155 2008 332 338
18. L. Goldman, B. Hashimoto, E.F. Cook, and A. Loscalzo Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale Circulation 64 1981 1227 1234
19. C. Raphael, C. Briscoe, J. Davies, Z. Ian Whinnett, C. Manisty, and R. Sutton Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure Heart 93 2007 476 482
20. S. Macran, H. Weatherly, and P. Kind Measuring population health: a comparison of three generic health status measures Med Care 41 2003 218 231
21. M. Herdman, C. Gudex, A. Lloyd, M. Janssen, P. Kind, and D. Parkin Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20 2011 1727 1736